115 related articles for article (PubMed ID: 32864761)
1. The clinical and pathological features of plasma cell myeloma post solid organ transplantation.
Ofori K; Soderquist CR; Murty VV; Park D; Vlad G; Leeman-Neill RJ; Lentzsch S; Alobeid B; Bhagat G
Am J Hematol; 2020 Dec; 95(12):1531-1541. PubMed ID: 32864761
[TBL] [Abstract][Full Text] [Related]
2. Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders.
Sarkozy C; Kaltenbach S; Faurie P; Canioni D; Berger F; Traverse-Glehen A; Ghesquieres H; Salles G; Bachy E; Alyanakian MA; Hermine O; Neven B; Macintyre E; Romana S; Molina TJ; Suarez F; Asnafi V; Bruneau J
Genes Chromosomes Cancer; 2017 Mar; 56(3):221-230. PubMed ID: 27750397
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant lymphoproliferative disorders: clinicopathological analysis of 43 cases in a single center, 1990-2009.
Yoon SO; Yu E; Cho YM; Suh C; Kim KM; Han DJ; Lee SG; Huh J
Clin Transplant; 2012; 26(1):67-73. PubMed ID: 21269330
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?
Nelson BP; Nalesnik MA; Bahler DW; Locker J; Fung JJ; Swerdlow SH
Am J Surg Pathol; 2000 Mar; 24(3):375-85. PubMed ID: 10716151
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic analysis of the impact of CD23 expression in plasma cell myeloma with t(11;14)(q13;q32).
Buonaccorsi JN; Kroft SH; Harrington AM; VanTuinen P; Olteanu H
Ann Diagn Pathol; 2011 Dec; 15(6):385-8. PubMed ID: 21724429
[TBL] [Abstract][Full Text] [Related]
6. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
Mamzer-Bruneel MF; Lomé C; Morelon E; Levy V; Bourquelot P; Jacobs F; Gessain A; Mac Intyre E; Brousse N; Kreis H; Hermine O
J Clin Oncol; 2000 Nov; 18(21):3622-32. PubMed ID: 11054435
[TBL] [Abstract][Full Text] [Related]
7. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow findings of 23 Korean post-transplant lymphoproliferative disorder patients: a single-center experience.
Cho MC; Park CJ; Huh J; Chi HS; Jang S; Suh C; Lee KH; Lee JH; Seo JJ; Im HJ
Clin Transplant; 2012; 26(4):E381-7. PubMed ID: 22694766
[TBL] [Abstract][Full Text] [Related]
9. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center.
Leblond V; Sutton L; Dorent R; Davi F; Bitker MO; Gabarre J; Charlotte F; Ghoussoub JJ; Fourcade C; Fischer A
J Clin Oncol; 1995 Apr; 13(4):961-8. PubMed ID: 7707124
[TBL] [Abstract][Full Text] [Related]
10. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?
Leblond V; Davi F; Charlotte F; Dorent R; Bitker MO; Sutton L; Gandjbakhch I; Binet JL; Raphael M
J Clin Oncol; 1998 Jun; 16(6):2052-9. PubMed ID: 9626203
[TBL] [Abstract][Full Text] [Related]
11. Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma.
Dunphy CH; Nies MK; Gabriel DA
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):248-54. PubMed ID: 17721267
[TBL] [Abstract][Full Text] [Related]
12. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
[TBL] [Abstract][Full Text] [Related]
13. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome.
Dotti G; Fiocchi R; Motta T; Mammana C; Gotti E; Riva S; Cornelli P; Gridelli B; Viero P; Oldani E; Ferrazzi P; Remuzzi G; Barbui T; Rambaldi A
Transplantation; 2002 Oct; 74(8):1095-102. PubMed ID: 12438953
[TBL] [Abstract][Full Text] [Related]
14. Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance.
Goebel TE; Schiltz NK; Woodside KJ; Pillai AC; Caimi PF; Lazarus HM; Koroukian SM; Campagnaro EL
Clin Transplant; 2015 Sep; 29(9):851-7. PubMed ID: 26194021
[TBL] [Abstract][Full Text] [Related]
15. Plasma cell neoplasms presenting with masses: a study on morphology, expression of CD56 and cyclin D1, and presence of Epstein-Barr virus in 39 Thai patients in SiriraJ Hospital.
Pipatsakulroj W; Pradniwat K; Treetipsatit J
J Med Assoc Thai; 2013 Dec; 96(12):1583-91. PubMed ID: 24511724
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
17. Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades.
Michonneau D; Suarez F; Lambert J; Adam J; Brousse N; Canioni D; Anglicheau D; Martinez F; Snanoudj R; Legendre C; Hermine O; Mamzer-Bruneel MF
Nephrol Dial Transplant; 2013 Feb; 28(2):471-8. PubMed ID: 23129824
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study.
Maksten EF; Vase MØ; Kampmann J; d'Amore F; Møller MB; Strandhave C; Bendix K; Bistrup C; Thiesson HC; Søndergaard E; Hamilton-Dutoit S; Jespersen B
Transpl Int; 2016 Apr; 29(4):483-93. PubMed ID: 26749337
[TBL] [Abstract][Full Text] [Related]
19. Role of Epstein-Barr virus status and immunophenotypic studies in the evaluation of exfoliative cytology specimens from patients with post-transplant lymphoproliferative disorders.
Gibson SE; Picarsic J; Swerdlow SH; Pantanowitz L
Cancer Cytopathol; 2016 Jun; 124(6):425-35. PubMed ID: 26992116
[TBL] [Abstract][Full Text] [Related]
20. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin.
Chadburn A; Suciu-Foca N; Cesarman E; Reed E; Michler RE; Knowles DM
Am J Pathol; 1995 Dec; 147(6):1862-70. PubMed ID: 7495309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
